Tag

UF Innovate | Sid Martin Biotech

Oragenics Awarded a $250,000 Grant From the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics

UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc., announced that it was awarded a small business innovation research grant in the amount of $250,000 (Computer-aided Design for Improved Lantibiotics R41GM136034) for the company’s continued research and development of lantibiotics, including its collaborative program with the Biomolecular Sciences Institute at Florida International University (FIU).

Can Handheld DNA Testing Technology Stand Up to Seafood Fraud?

When LeeAnn Applewhite started running DNA analysis on commercial seafood samples in 2015, 75 percent of them – species ranging from grouper and snapper to catfish and shrimp – were mislabeled. “We were testing thousands of samples, and some of it was unintentional mislabeling; it was a bycatch species with [species like] grouper or snapper but the whole load was not erroneously labeled,” said Applewhite, co-founder and president of UF Innovate | Sid Martin Biotech graduate Applied Food Technologies.

Axogen RECON(SM) Clinical Study Completes Subject Follow-Up

UF startup and UF Innovate | Sid Martin Biotech graduate Axogen, a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, announced that the RECON Clinical Study supporting its Biologics License Application (BLA) for Avance Nerve Graft has completed follow-up of study subjects.

Oragenics’ SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice With Intramuscular and Intranasal Adjuvants

UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announces that the stabilized pre-fusion spike protein trimer produced by its Canadian collaborator and licensed by the company from the National Institutes of Health (NIH) generates neutralizing antibodies in mice after immunization against SARS-CoV-2, when administered with several novel intramuscular (IM) and intranasal (IN) adjuvants.